[1] Wong, S. L., Marshall, L. Z., & Lawson, K. A. (2018). Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas Medicaid. The American Journal of Managed Care, 24(8 Spec No.), SP309–SP314.

[2] Yu, Y. B., Liu, J., Fu, G. H., Fang, R. Y., Gao, F., & Chu, H. M. (2018). Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial. Medicine, 97(46), e12841. https://doi.org/10.1097/MD.0000000000012841

[3] Chen, A., Stecker, E., & A Warden, B. (2020). Direct oral anticoagulant use: A practical guide to common clinical challenges. Journal of the American Heart Association, 9(13), e017559. https://doi.org/10.1161/JAHA.120.017559

[4] Robinson, A., McCarty, D., & Douglas, J. (2016). Novel oral anticoagulants for acute coronary syndrome. Therapeutic Advances in Cardiovascular Disease, 11(1), 4–11. https://doi.org/10.1177/1753944716671484

[5] Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H. C., Joyner, C. D., Wallentin, L., & the RE-LY Steering Committee and Investigators. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361(12), 1139–1151. https://doi.org/10.1056/NEJMoa0905561

[6] Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A., Califf, R. M., & the ROCKET AF Investigators. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 365(10), 883–891. https://doi.org/10.1056/NEJMoa1009638

[7] Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., Hornick, P., & the ADVANCE-2 investigators. (2010). Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE- 2): A randomised double-blind trial. Lancet, 375(9717), 807–815. https://doi.org/10.1016/S0140- 6736(09)62125-5

[8] Larsen, T. B., Skjøth, F., Nielsen, P. B., Kjældgaard, J. N., & Lip, G. Y. (2016). Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. BMJ (Clinical Research Ed.), 353, i3189. https://doi.org/10.1136/bmj.i3189

[9] Eek, A. K., Øie, E., & Granas, A. G. (2018). Prescribing of NOACs has outnumbered warfarin: Exploringhow physicians choose anticoagulant treatments. European Journal of Clinical Pharmacology, 74, 323–330. https://doi.org/10.1007/s00228-017-2374-4

[10] Chan, K. E., Edelman, E. R., Wenger, J. B., Thadhani, R. I., & Maddux, F. W. (2015). Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation, 131(11), 972–979. https://doi.org/10.1161/CIRCULATIONAHA.114.014113

[11] Rose, D. K., & Bar, B. (2018). Direct oral anticoagulant agents: Pharmacologic profile, indications, coagulation monitoring, and reversal agents. Journal of Stroke and Cerebrovascular Diseases, 27(8), 2049– 2058. jstrokecerebrovasdis.2018.04.004 https://doi. org/10.1016/j.jstrokecerebrovasdis.2018.04.004

[12] Paul, C., Baby, M., Anthraper, A. R., & K, K. (2020). NOACs: An emerging class of oral anticoagulantsa review article. Future Journal of Pharmaceutical Sciences, 6, 1–7. https://doi.org/10.1186/s43094-020- 00114-1

[13] Clinical Excellence Commission. (2023). Direct Oral Anticoagulant (DOAC) Guidelines. https://www.cec.health.nsw.gov.au/keeppatients- safe/medication-safety/high-riskmedicines/ anticoagulants

[14] Grześk, G., Rogowicz, D., Wołowiec, Ł., Ratajczak, A., Gilewski, W., Chudzińska, M., Sinkiewicz, A., & Banach, J. (2021, August 8). The clinical significance of drug-food interactions of direct oral anticoagulants. International Journal of Molecular Sciences, 22(16), 8531. https://doi.org/10.3390/ijms22168531

[15] Trujillo, T., & Dobesh, P. P. (2014, September). Clinical use of rivaroxaban: Pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs, 74(14), 1587–1603. https://doi.org/10.1007/s40265-014-0278-5. Erratum in: Drugs, 74(15).

[16] Chen, A., Stecker, E., & A Warden, B. (2020, July 7). Direct oral anticoagulant use: A practical guide to common clinical challenges. Journal of the American Heart Association, 9(13), e017559. https://doi.org/10.1161/JAHA.120.017559

[17] Wigle, P., Hein, B., & Bernheisel, C. R. (2019, October 1). Anticoagulation: Updated guidelines for outpatient management. American Family Physician, 100(7), 426–434.

[18] Charan, J., & Biswas, T. (2013). How to calculate sample size for different study designs in medical research? Indian Journal of Psychological Medicine, 35(2), 121–126. https://doi.org/10.4103/0253- 7176.116232

[19] El-Bardissy, A., Elewa, H., Mohammed, S., Shible, A., Imanullah, R., & Mohammed, A. M. (2018). A survey on the awareness and attitude of physicians on direct oral anticoagulants in Qatar. Clinical and Applied Thrombosis/Hemostasis, 24(9), 255S– 260S. https://doi.org/10.1177/1076029618807575

[20] Ye, S., Wang, T., Liu, A., Yu, Y., Pan, Z., & Gu, J. (2020). A study of knowledge, attitudes, and practices of primary care physicians toward anticoagulant therapy in patients with non-valvular atrial fibrillation in Shanghai, China. BMC Family Practice, 21, 165. https://doi.org/10.1186/s12875-020-01236-4

[21] Alnemari, R., Banheem, A., Mullaniazee, N., Alghamdi, S., Rajkhan, A., Basfar, O., & Basnawi, M. (2018). Knowledge, attitude and practice of physicians towards oral anti-coagulants in Taif city, Saudi Arabia. International Journal of Advances in Medicine, 5(5), 1086–1092. https://doi.org/10.18203/2349-3933.ijam20183884

[22] Piran, S., Schulman, S., Salib, M., Delaney, J., Panju, M., & Pai, M. (2017). Direct oral anticoagulants in the real world: Insights into Canadian health care providers’ understanding of medication dosing and use. Canadian Journal of General Internal Medicine, 12(3), 23–27. https://doi.org/10.22374/cjgim.v12i3.201

[23] Wigle, P., Hein, B., & Bernheisel, C. R. (2019). Anticoagulation: Updated guidelines for outpatient management. American Family Physician, 100(7), 426–434.

[24] Zappulla, P., & Calvi, V. (2021). Gastrointestinal bleeding and direct oral anticoagulants amongpatients with atrial fibrillation: Risk, prevention, management, and quality of life. TH Open: Companion Journal to Thrombosis and Haemostasis, 5(2), e200–e210. https://doi.org/10.1055/s-0041-1730035

[25] Connell, N. T., & Butera, J. N. (2015). Attending physician attitudes toward choice of oral anticoagulant for the treatment of venous thromboembolism. Rhode Island Medical Journal, 98(7), 32–36.

[26] Aursulesei, V., & Costache, I. I. (2019). Anticoagulation in chronic kidney disease: From guidelines to clinical practice. Clinical Cardiology, 42(8), 774–782. https://doi.org/10.1002/clc.23196

[27] Dewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J. P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., Tijsen, J. G., van ’t Hof, A. W., ten Berg, J. M., & the WOEST study investigators. (2013). Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet, 381(9872), 1107–1115. https://doi.org/10.1016/S0140- 6736(12)62177-1

[28] Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., Korjian, S., Daaboul, Y., Lip, G. Y., Cohen, M., Husted, S., Peterson, E. D., & Fox, K. A. (2016). Prevention of bleeding in patients with atrial fibrillation undergoing PCI. The New England Journal of Medicine, 375(25), 2423–2434. https://doi.org/10.1056/NEJMoa1611594

[29] Raval, A. N., Cigarroa, J. E., Chung, M. K., Diaz- Sandoval, L. J., Diercks, D., Piccini, J. P., Jung, H. S., Washam, J. B., Welch, B. G., Zazulia, A. R., Collins, S. P., & the American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Quality of Care and Outcomes Research. (2017). Management of patients on non–vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: A scientific statement from the American Heart Association. Circulation, 135(10), e604–e633. https://doi.org/10.1161/CIR.0000000000000477